413 related articles for article (PubMed ID: 11875482)
1. AIDS vaccine models: challenging challenge viruses.
Feinberg MB; Moore JP
Nat Med; 2002 Mar; 8(3):207-10. PubMed ID: 11875482
[No Abstract] [Full Text] [Related]
2. Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine.
Bhardwaj N; Walker BD
Nat Med; 2003 Jan; 9(1):13-4. PubMed ID: 12514710
[No Abstract] [Full Text] [Related]
3. Protection of macaques against vaginal SHIV challenge by systemic or mucosal and systemic vaccinations with HIV-envelope.
Barnett SW; Srivastava IK; Kan E; Zhou F; Goodsell A; Cristillo AD; Ferrai MG; Weiss DE; Letvin NL; Montefiori D; Pal R; Vajdy M
AIDS; 2008 Jan; 22(3):339-48. PubMed ID: 18195560
[TBL] [Abstract][Full Text] [Related]
4. The primate connection.
Trivedi B
Nature; 2010 Jul; 466(7304):S5. PubMed ID: 20631704
[No Abstract] [Full Text] [Related]
5. Characterization of simian and human immunodeficiency chimeric viruses re-isolated from vaccinated macaque monkeys after challenge infection.
Kwofie TB; Miura T; Ibuki K; Enose Y; Suzuki H; Ui M; Kuwata T; Hayami M
Arch Virol; 2002 Jun; 147(6):1091-104. PubMed ID: 12111421
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic dendritic-cell vaccine for simian AIDS.
Lu W; Wu X; Lu Y; Guo W; Andrieu JM
Nat Med; 2003 Jan; 9(1):27-32. PubMed ID: 12496959
[TBL] [Abstract][Full Text] [Related]
7. Vaccines. Monkey puzzles.
Cohen J
Science; 2002 Jun; 296(5577):2325-6. PubMed ID: 12089425
[No Abstract] [Full Text] [Related]
8. 25 years of HIV research! ... and what about a vaccine?
Appay V
Eur J Immunol; 2009 Aug; 39(8):1999-2003. PubMed ID: 19672891
[TBL] [Abstract][Full Text] [Related]
9. CD4+ T-cell subsets: what really counts in preventing HIV disease?
Mason RD; De Rose R; Kent SJ
Expert Rev Vaccines; 2008 Mar; 7(2):155-8. PubMed ID: 18324885
[No Abstract] [Full Text] [Related]
10. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial.
Matano T; Kobayashi M; Igarashi H; Takeda A; Nakamura H; Kano M; Sugimoto C; Mori K; Iida A; Hirata T; Hasegawa M; Yuasa T; Miyazawa M; Takahashi Y; Yasunami M; Kimura A; O'Connor DH; Watkins DI; Nagai Y
J Exp Med; 2004 Jun; 199(12):1709-18. PubMed ID: 15210746
[TBL] [Abstract][Full Text] [Related]
11. Human and simian immunodeficiency virus-infected chimpanzees do not have increased intracellular levels of beta-chemokines in contrast to infected humans.
Ondoa P; Vereecken C; Fransen K; Colebunders R; van der Groen G; Heeney JL; Kestens L
J Med Virol; 2003 Mar; 69(3):297-305. PubMed ID: 12526038
[TBL] [Abstract][Full Text] [Related]
12. AIDS vaccine development in primate models.
Almond NM; Heeney JL
AIDS; 1998; 12 Suppl A():S133-40. PubMed ID: 9632994
[No Abstract] [Full Text] [Related]
13. Immunization with HIV-1 SF162-derived Envelope gp140 proteins does not protect macaques from heterologous simian-human immunodeficiency virus SHIV89.6P infection.
Xu R; Srivastava IK; Kuller L; Zarkikh I; Kraft Z; Fagrouch Z; Letvin NL; Heeney JL; Barnett SW; Stamatatos L
Virology; 2006 Jun; 349(2):276-89. PubMed ID: 16527321
[TBL] [Abstract][Full Text] [Related]
14. Reversion of immune escape HIV variants upon transmission: insights into effective viral immunity.
Kent SJ; Fernandez CS; Dale CJ; Davenport MP
Trends Microbiol; 2005 Jun; 13(6):243-6. PubMed ID: 15936652
[TBL] [Abstract][Full Text] [Related]
15. Preventing AIDS but not HIV-1 infection with a DNA vaccine.
Shen X; Siliciano RF
Science; 2000 Oct; 290(5491):463-5. PubMed ID: 11183769
[TBL] [Abstract][Full Text] [Related]
16. Towards the development of a therapeutic vaccine for the treatment of HIV-1 infection: are we closer than ever?
Egan MA
Expert Rev Vaccines; 2007 Jun; 6(3):289-91. PubMed ID: 17542741
[No Abstract] [Full Text] [Related]
17. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
Yang OO
Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
[No Abstract] [Full Text] [Related]
18. Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Zhan X; Martin LN; Slobod KS; Coleclough C; Lockey TD; Brown SA; Stambas J; Bonsignori M; Sealy RE; Blanchard JL; Hurwitz JL
Vaccine; 2005 Nov; 23(46-47):5306-20. PubMed ID: 16095768
[TBL] [Abstract][Full Text] [Related]
19. Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys.
Letvin NL; Huang Y; Chakrabarti BK; Xu L; Seaman MS; Beaudry K; Korioth-Schmitz B; Yu F; Rohne D; Martin KL; Miura A; Kong WP; Yang ZY; Gelman RS; Golubeva OG; Montefiori DC; Mascola JR; Nabel GJ
J Virol; 2004 Jul; 78(14):7490-7. PubMed ID: 15220422
[TBL] [Abstract][Full Text] [Related]
20. Is an HIV vaccine possible?
McMichael AJ; Hanke T
Nat Med; 1999 Jun; 5(6):612-4. PubMed ID: 10371492
[No Abstract] [Full Text] [Related]
[Next] [New Search]
